Role of serum and urinary orsomucoid protein A in psoriatic arthritis patients and their relation to disease activity.

Background: The musculoskeletal disorder known as psoriatic arthritis (PsA) is heterogeneous and can cause a range of symptoms, such as axial involvement, dactylitis, enthesitis, and arthritis. For as many as thirty percent of patients, psoriasis or nail disease coexist with musculoskeletal complaints. Serum and urine ORM levels have been shown to have an inflammatory role in psoriasis, making them one of the few biomarkers associated with the disease. However, no research has been done on PsA patients, therefore our goal was to evaluate the levels of ORM in PsA patients' serum and urine and their relationship to disease activity. Methods: Patients participated in a case control study at the Zagazig University Hospitals' Rheumatology and Rehabilitation Department. They were divided into two equal groups (control and PsA). Psoriatic arthritis disease activity index (DAPSA) was used to measure PsA activity, while the Psoriasis Area and Severity Index (PASI) was used to measure skin severity. Plain X-ray oblique view and MRI by STIR technique on sacroiliac joint were done. Orsomucoid urine / creatinine urine ratio and detection of Serum and urinary orsomucoid protein A by Human Orsomucoid ELISA later were done. Results: PsA had considerably greater serum, urine orsomucoid protein A level, and urine orsomucoid/creatinine ratio than controls. Urine Orsomucoid and disease activity showed a strong positive connection.Conclusion: Orsomucoid may be a useful biomarker for psoriatic arthritis patients to assess the disease's activity and may play a part in the pathophysiology of the condition.